- Home
- SNSE vs APRE Comparison
SNSE vs APRE Comparison
Compare SNSE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- APRE
- Stock Information
- Founded
- SNSE 2005
- APRE 2006
- Country
- SNSE United States
- APRE United States
- Employees
- SNSE N/A
- APRE N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNSE Health Care
- APRE Health Care
- Exchange
- SNSE Nasdaq
- APRE Nasdaq
- Market Cap
- SNSE 9.3M
- APRE 8.4M
- IPO Year
- SNSE 2021
- APRE 2019
- Fundamental
- Price
- SNSE $0.38
- APRE $1.62
- Analyst Decision
- SNSE Strong Buy
- APRE Strong Buy
- Analyst Count
- SNSE 4
- APRE 2
- Target Price
- SNSE $4.25
- APRE $15.50
- AVG Volume (30 Days)
- SNSE 8.3M
- APRE 29.8K
- Earning Date
- SNSE 05-08-2025
- APRE 05-13-2025
- Dividend Yield
- SNSE N/A
- APRE N/A
- EPS Growth
- SNSE N/A
- APRE N/A
- EPS
- SNSE N/A
- APRE N/A
- Revenue
- SNSE N/A
- APRE $1,502,581.00
- Revenue This Year
- SNSE N/A
- APRE N/A
- Revenue Next Year
- SNSE N/A
- APRE N/A
- P/E Ratio
- SNSE N/A
- APRE N/A
- Revenue Growth
- SNSE N/A
- APRE 157.63
- 52 Week Low
- SNSE $0.25
- APRE $1.41
- 52 Week High
- SNSE $1.94
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- SNSE 48.32
- APRE 36.93
- Support Level
- SNSE $0.33
- APRE $1.41
- Resistance Level
- SNSE $0.39
- APRE $1.59
- Average True Range (ATR)
- SNSE 0.05
- APRE 0.11
- MACD
- SNSE 0.00
- APRE 0.03
- Stochastic Oscillator
- SNSE 52.68
- APRE 48.04
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.